Protagonist Therapeutics, Inc Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Protagonist Therapeutics, Inc (PTGX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 2.00% for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-07.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2017-11-07
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2017-09-30 was 2.00%, a 44.93% increase year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2017-03-31 was 2.07%, a 59.23% increase year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-09-30 was 1.38%.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-06-30 was 1.38%.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2014 was 1.89%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|
| 2017-09-30 | 2.00% 10-Q · filed 2017-11-07 | ||||
| 2017-03-31 | 2.07% 10-Q · filed 2017-05-10 | ||||
| 2016-09-30 | 1.38% 10-Q · filed 2017-11-07 | 1.28% 10-Q · filed 2016-11-14 | |||
| 2016-06-30 | 1.38% 10-Q · filed 2017-08-08 | ||||
| 2016-03-31 | 1.30% 10-Q · filed 2017-05-10 | ||||
| 2015-09-30 | 1.57% 10-Q · filed 2016-11-14 | ||||
| 2015-06-30 | 1.57% 10-Q · filed 2016-09-15 | ||||
| 2014-12-31 | 1.89% 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |